<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1405245287
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VARIVAX 1350 PFU VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VARICELLA VIRUS VACCINE LIVE (OKA-MERCK)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1350
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        PFU/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular and intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for suspension for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        152.1
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="MERCK SHARP &amp; DOHME" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J07BK01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VARIVAX is a vaccine to help protect adults and children against chickenpox (varicella). Vaccines are used to protect you or your child against infectious diseases.</p><p>&nbsp;</p><p>VARIVAX can be administered to persons 12 months of age or older.</p><p>&nbsp;</p><p>VARIVAX may also be administered to infants from 9 months of age under special circumstances, such as to conform with national vaccination schedules or in outbreak situations.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:line id="Line_x0020_7" o:spid="_x0000_s1027"
 style='position:absolute;flip:x;z-index:251658240;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' from="390pt,11pt" to="438pt,29pt"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:stroke startarrowwidth="narrow" startarrowlength="short" endarrow="block"
  endarrowwidth="narrow" endarrowlength="short"/>
</v:line><![endif]--><!--[if gte vml 1]><v:line id="Line_x0020_6" o:spid="_x0000_s1026"
 style='position:absolute;flip:x;z-index:251657216;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' from="378pt,20pt" to="438pt,29pt"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:stroke startarrowwidth="narrow" startarrowlength="short" endarrow="block"
  endarrowwidth="narrow" endarrowlength="short"/>
</v:line><![endif]-->It may also be given to persons who have no history of chickenpox, but who have been exposed to someone who has chickenpox.</p><p>Vaccination within 3 days of exposure may help prevent chickenpox or reduce the severity of disease, resulting in fewer skin lesions and shorter duration of illness. In addition, there is limited information that being vaccinated up to 5 days after exposure may reduce disease severity.</p><p>&nbsp;</p><p>As with other vaccines, VARIVAX does not completely protect all individuals from naturally acquired chickenpox.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p><strong>Do not use VARIVAX if:</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child are allergic to any varicella vaccine, to any of the ingredients of this vaccine (listed in section 6), or neomycin (which may be present as a trace residue).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child have a blood disorder or any type of malignant cancers including leukaemia and lymphomas that affects the immune system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child are receiving immunosuppressive therapy (including high doses of corticosteroids).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child have any illness (such as Human Immunodeficiency Virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS)) or take any medicine that weakens the immune system. Whether you or your child receives the vaccine will depend upon the level of your immune defences.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child have a family member born with immunodeficiency, or there is a family history of immunodeficiency.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child have active untreated tuberculosis.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you or your child have a temperature higher than 38.5&deg;C; however, low-grade fever itself is not a reason not to be vaccinated.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are pregnant. In addition, pregnancy should be avoided for 1 month after vaccination.</p><p>&nbsp;</p><p><strong>Warnings and precautions:</strong></p><p><u>&nbsp;</u></p><p>In rare circumstances, it is possible to catch chickenpox, including severe chickenpox, from a person who has been vaccinated with VARIVAX. This may occur in persons who have not previously been vaccinated or had chickenpox, as well as persons who fall into one of the following categories:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; individuals with a weakened immune system.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pregnant women who have never had chickenpox.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; newborn babies whose mothers have never had chickenpox.</p><p>&nbsp;</p><p>Whenever possible, individuals who have been vaccinated with VARIVAX should attempt to avoid close contact, for up to 6 weeks following the vaccination, with anyone who falls into one of the categories above. Tell your doctor if there is anyone who falls into one of the categories above and is expected to be in close contact with the person being vaccinated.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before you or your child receive VARIVAX:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you or your child have a weakened immune system (such as HIV infection). You or your child should be closely monitored as the response to the vaccine may not be sufficient to ensure protection against the illness (see section 2 &quot;Do not use VARIVAX if&quot;).</p><p>&nbsp;</p><p><strong>Other medicines (or other vaccines) and VARIVAX:</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you or your child are taking or have recently taken any other medicines (or other vaccines).</p><p>&nbsp;</p><p>If any type of vaccine is due to be given at the same time as VARIVAX, your doctor or health care professional will advise you whether this can be given or not. VARIVAX may be given at the same time as the following routine childhood vaccinations: measles, mumps and rubella vaccine (MMR), vaccines against <em>Haemophilus influenza </em>type b, hepatitis B, diphtheria, tetanus, pertussis (whooping cough) and polio vaccine that is given by mouth.</p><p>&nbsp;</p><p>Vaccination should be deferred for at least 5 months after any blood or plasma transfusions, or administration of normal human immune globulin (a sterile solution of naturally produced antibodies taken from donated human blood) or varicella zoster immune globulin (VZIG) have been given.</p><p>&nbsp;</p><p>Following vaccination with VARIVAX, you or your child should not receive any immune globulin, including VZIG, for 1 month thereafter unless your doctor decides it is necessary.</p><p>&nbsp;</p><p>Vaccine recipients should avoid products that contain aspirin (salicylates) for 6 weeks after vaccination with VARIVAX as this may cause a serious condition called Reye syndrome which can affect all your body organs.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>&nbsp;</p><p>VARIVAX<strong> </strong>should<strong> </strong>not be administered to pregnant women.</p><p>&nbsp;</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before the vaccination is given. Also, it is important that you do not become pregnant within one month after having the vaccine. During this time you should use an effective method of birth control to avoid pregnancy.</p><p>&nbsp;</p><p>Inform your doctor if you are breast-feeding or if you intend to breast-feed. Your doctor will decide if you should receive VARIVAX.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p><strong>&nbsp;</strong></p><p>There is no information to suggest that VARIVAX<em> </em>will affect your ability to drive or use machines.</p><p>&nbsp;</p><p><strong>VARIVAX contains sodium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><strong>VARIVAX contains potassium</strong></p><p>&nbsp;</p><p>This medicine contains less than 1 mmol potassium (39&nbsp;mg) per dose, that is to say essentially &lsquo;potassium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>VARIVAX will be administered by your doctor or health care professional.</p><p><strong>&nbsp;</strong></p><p>VARIVAX is given by injection as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infants from 9 months to 12 months of age:</p><p>Under special circumstances (to conform with national vaccination schedules or in outbreaks of chickenpox), VARIVAX may be administered between 9 and 12 months of age. To ensure optimal protection against chickenpox, two doses of VARIVAX are needed and should be given at least three months apart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children from 12 months to 12 years of age:</p><p>To ensure optimal protection against chickenpox, two doses of VARIVAX should be given at least one month apart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children from 12 months to 12 years of age with asymptomatic HIV:</p><p>VARIVAX should be given as two doses by injection 12 weeks apart. Please ask your healthcare provider for more information.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Teenagers 13 years of age and older and adults:</p><p>VARIVAX is given as two doses by injection. The second dose should be given 4 to 8 weeks after the first dose.</p><p>&nbsp;</p><p>The number and timing of doses should be determined by your doctor, using the official recommendations.</p><p>&nbsp;</p><p>VARIVAX should not be given to children under 9 months of age.</p><p>&nbsp;</p><p>VARIVAX should be injected into the muscle or under the skin either in the area of the outer thigh or of the upper arm. Usually for injections into the muscle, the thigh area is preferred in young children, whereas for older individuals, the upper arm area is the preferred injection site.</p><p>&nbsp;</p><p>If you have a blood clotting disorder or low levels of platelets in your blood, the injection will be given under the skin.</p><p>&nbsp;</p><p>Your doctor or health care professional will take care that VARIVAX is not injected into the bloodstream.</p><p>&nbsp;</p><p><strong>If you use more VARIVAX</strong><em> </em><strong>than you should</strong></p><p><strong>&nbsp;</strong></p><p>Overdose is very unlikely because the vaccine is provided in single dose vials and is given by a doctor or health care professional.</p><p>&nbsp;</p><p><strong>If you think you have missed a dose of VARIVAX</strong></p><p><strong>&nbsp;</strong></p><p>Contact your doctor who will decide if a dose is required and when to give it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all vaccines and medicines, this vaccine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Very rarely (reported in less than 1 in 10,000 people), a severe allergic reaction may occur with symptoms that may include facial swelling, low blood pressure, and difficulty breathing, with or without rash. These reactions often occur very soon after the injection. If any of these symptoms or other serious symptoms are noticed after vaccination, you must seek immediate medical attention.</p><p><strong><u>&nbsp;</u></strong></p><p>Tell your doctor if you notice any of the following rare or very rare side effects:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bruising or bleeding more easily than normal; red or purple, flat, pinhead spots under the skin, severe paleness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe skin rash (ulcers and blistering that may involve the eyes, mouth, and/or genitals; red, often itchy spots which start on the limbs and sometimes on the face and the rest of the body) (Stevens‑Johnson syndrome; erythema multiforme)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness, abnormal sensations, tingling in the arms, legs, and upper body (Guillain-Barr&eacute; syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, feeling sick, vomiting, headache, stiff neck and sensitivity to light (meningitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stroke</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures (fits) with or without a fever</p><p>&nbsp;</p><p>The following side effects have been observed:</p><p>&nbsp;</p><p>Very common reactions (reported by more than 1 out of 10 people) were:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site redness of the skin, pain/sensitivity to touch/soreness, and swelling</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Common reactions (reported by less than 1 out of 10 but more than 1 out of 100 people) were:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upper respiratory tract infection (nose, throat, airway)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash, rash with flat, red skin and small confluent bumps, varicella-like rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site rash, itching at the injection site</p><p>&nbsp;</p><p>Uncommon reactions (reported by less than 1 out of 100 but more than 1 out of 1,000 people) were:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, drowsiness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; discharge and itching of the eyes with crusting of eyelids (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough, nasal congestion, chest congestion, runny nose, loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; upset stomach with vomiting, cramps, diarrhoea caused by a virus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, vomiting (gastroenteritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ear infection, sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crying, inability to sleep, sleep disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; varicella skin rash caused by virus (chicken pox), illness caused by a virus, inflammation of the skin, redness of the skin, hives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness/fatigue, generally feeling unwell, injection site reactions including hive-like rash, numbness, bleeding, bruising, hardened raised area of the skin, warm feeling, warm to touch</p><p>&nbsp;</p><p>Rare reactions (<em>reported by less than 1 out of 1,000 people but more than 1 out of 10,000 people</em>) were:</p><p>swollen glands, bruising or bleeding more easily than normal</p><p>agitation, sleeping too much, difficulty walking, seizures with a fever, shaking</p><p>swelling of eyelid, irritation of eye</p><p>&nbsp;ear pain</p><p>feeling of fullness in the nose sometimes with throbbing ache and facial pressure or pain (sinusitis), sneezing, runny nose (rhinitis), wheezing, swelling of the tubes relating to the lungs (bronchitis), lung infection, severe lung infection with fever, chills, cough, congestion and shortness of breath (pneumonia)</p><p>&nbsp;flu-like illness</p><p>&nbsp;stomach pain, upset stomach and feeling sick, blood in the stool, mouth ulcer</p><p>flushing, blisters, skin disorders (including bruising, and hives)</p><p>muscle/bone pain, aching muscles, stiffness</p><p>njection site reactions including changes in skin colour</p><p>&nbsp;</p><p>Side effects that have been reported during marketed use of VARIVAX include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; illnesses affecting the nervous system (brain and/or spinal cord) such as sagging facial muscles and drooping eyelid on one side of the face (Bell&#39;s palsy), walking unsteadily, dizziness, syncope, tingling or numbness of the hands and feet, inflammation of the brain (encephalitis), inflammation of the coverings of the brain and spinal cord not caused by bacterial infection (aseptic meningitis),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shingles, sore throat (pharyngitis), purple or red‑brown spots visible through the skin (Henoch‑Sch&ouml;nlein purpura), secondary bacterial infections of the skin and soft tissues (including cellulitis), chickenpox (varicella), aplastic anaemia, which may include bruising or bleeding more easily than normal; red or purple, flat, pinhead spots under the skin; severe paleness</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA. By reporting side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this vaccine out of sight and reach of children.</p><p>&nbsp;</p><p>Do not use this vaccine after the expiry date which is stated on the box after EXP.</p><p>&nbsp;</p><p>Store and transport refrigerated (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C). Do not freeze. Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>After reconstitution, the vaccine should be used immediately. However, the in-use stability has been demonstrated for 30&nbsp;minutes between +20&nbsp;&deg;C and +25&nbsp;&deg;C.</p><p>&nbsp;</p><p>Do not throw away any vaccines via wastewater or household waste. Ask your pharmacist how to throw away vaccines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p><strong>What VARIVAX contains</strong></p><p><strong>&nbsp;</strong></p><p><strong>The active ingredient is</strong>: live attenuated varicella virus (Oka/Merck strain) (produced in MRC-5 human diploid cells).</p><p>&nbsp;</p><p>Each 0.5 mL dose of reconstituted vaccine contains: a minimum of 1,350 PFU (plaque forming units) of varicella virus (Oka/Merck strain).</p><p><strong>The other ingredients are</strong>:</p><p><strong><em><u>&nbsp;</u></em></strong></p><p><strong><em><u>Powder:</u></em></strong></p><p>Sucrose (17 mg)</p><p>Hydrolyzed Gelatin (8.3 mg)</p><p>Urea (3.5 mg)</p><p>Sodium chloride (2.1 mg)</p><p>Monosodium L-glutamate (0.33 mg)</p><p>Sodium Phosphate Dibasic (0.30 mg)</p><p>Potassium Phosphate Monobasic (53 &mu;g)</p><p>Potassium chloride (53 &mu;g)</p><p>&nbsp;</p><p>Residual components in trace quantities: neomycin.</p><p>&nbsp;</p><p><strong><em><u>Solvent</u></em></strong><strong>:</strong></p><p>Water for injections</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pharmaceutical form: powder and solvent for suspension for injection

The vaccine consists of a white to off-white powder in a vial and a clear colourless liquid solvent  in a vial. The product is available in packs of one or 10 doses.


  
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer </strong></p><p><strong>Marketing Authorization Holder:<br />Merck Sharp &amp; Dohme LLC<br />770 Sumneytown Pike<br />P.O. Box 4<br />West Point, PA 19486, US</strong></p><p><br /><strong>Manufacturers:<br />Merck Sharp &amp; Dohme LLC<br />770 Sumneytown Pike<br />P.O. Box 4<br />West Point, PA 19486, US</strong></p><p><br /><strong>And/Or:<br />Merck Sharp &amp; Dohme LLC<br />5325 Old Oxford Road<br />Durham, NC 27712, US</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                September 2022

To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa

•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to instructions is dangerous for you.
	Follow strictly the doctor’s prescription, the method of use and the instructions  of the pharmacist who sold the medicament.
	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
	Do not by yourself interrupt the period of treatment prescribed for you.
	Do not repeat the same prescription without consulting your doctor.
	Keep all medicaments out of reach of children.
Council of Arab Health Ministers 
Union of Arab Pharmacists
This patient information leaflet is approved by the Saudi Food and Drug Authority

The following information is intended for health care professionals only:

Instructions

Before reconstitution, the vial contains a white to off-white powder and the pre-filled syringe contains a clear, colourless liquid solvent. The reconstituted vaccine is a clear, colourless to pale yellow liquid.

Avoid contact with disinfectants.

To reconstitute the vaccine, use only the solvent provided in the pre-filled syringe.

It is important to use a separate sterile syringe and needle for each patient to prevent transmission of infectious agents from one individual to another.

One needle should be used for reconstitution and a separate, new needle for injection.

Directions for the vaccine preparation 

To attach the needle, it should be firmly placed on the tip of the syringe and secured by rotating a quarter of a turn (90°).

Inject the entire content of the pre-filled syringe into the vial containing the powder. Gently agitate to mix thoroughly.

The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation in physical appearance. The vaccine must not be used if any particulate matter is noted or if the appearance is not a clear colourless to pale yellow liquid after reconstitution.

It is recommended that the vaccine be administered immediately after reconstitution, to minimise loss of potency. Discard if reconstituted vaccine is not used within 30 minutes.

Do not freeze the reconstituted vaccine.

Withdraw the entire content of the vial into a syringe, change the needle, and inject the vaccine by subcutaneous or intramuscular route.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

See also section 3 How to use VARIVAX





            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">فاريفاكس هو لقاح يساعد على وقاية البالغين والأطفال ضد الحماق (جدري الماء). وتستخدم اللقاحات عمومًا لوقايتك أنت أو طفلك ضد الأمراض المعدية.</p><p dir="RTL">يمكن إعطاء فاريفاكس للأشخاص بدءًا من عمر 12 شهرا وما فوق.</p><p dir="RTL">ويمكن أيضا إعطاء فاريفاكس للرضع بدءًا من عمر 9 شهور في ظروف خاصة، مثل الرغبة في التوافق مع متطلبات جداول التطعيم الوطنية أو في حالات تفشي المرض.</p><p dir="RTL">ويمكن أيضا أن يُعطى للأشخاص الذين ليس لديهم تاريخ في الإصابة بجدري الماء ، ولكنهم تعرضوا لشخص مصاب به.</p><p dir="RTL">التطعيم في غضون 3 أيام من التعرض للمرض قد يساعد على منع الإصابة به أو التقليل من شدته، مما يؤدي إلى الحد من الطفح الجلدي و التقليل من مدة المرض. وبالإضافة إلى ذلك، هناك معلومات محدودة تفيد بأن التطعيم خلال الخمسة أيام الأولى بعد التعرض قد يقلل من شدة المرض.</p><p dir="RTL">وكما هو الحال مع اللقاحات الأخرى، فاريفاكس لا يحمي تماما جميع الأفراد من جدري الماء الذي ينتج عن الإصابة بشكل طبيعي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم فاريفاكس إذا: </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو لدى طفلك حساسية&nbsp; نحو أي لقاح من لقاحات جدري الماء ، نحو أي من مكونات هذا اللقاح أو أي من المكونات الأخرى المدرجة في القسم &nbsp;6 او النيومايسين (قد يكون بكميات ضئيلة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت أنت أو طفلك تعاني من اضطراب في الدم أو من أي نوع من أنواع السرطان الخبيثة بما في ذلك سرطان الدم والأورام اللمفاوية التي تؤثر على الجهاز المناعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتلقى أنت أو طفلك العلاج المثبّط للمناعة (بما في ذلك جرعات عالية من الستيروئيدات القشرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت أنت أو طفلك مصاب بأي مرض (مثل فيروس نقص المناعة البشرية (إش أي في HIV ) أو متلازمة نقص المناعة المكتسب (الإيدز)) أو تتناول أي دواء يضعف جهاز المناعة. وسواء &nbsp;كنت ستتلقى اللقاح أنت أو طفلك سوف يعتمد ذلك على مستوى الدفاعات المناعية الخاصة بكما.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أو لدى طفلك&nbsp; فرد من أفراد العائلة مصاب بنقص المناعة الأولية &quot;بالولادة&quot;، أو أن هناك تاريخ عائلي من نقص المناعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت أنت أو طفلك مصاب بمرض السل النشط غير المعالج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك أنت أو طفلك ارتفاع في درجة حرارة أعلى من 38.5 درجة مئوية. ولكن، وجود حمى منخفضة الدرجة لا يعد سببًا&nbsp; لعدم التطعيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; كنت حاملاً. وبالإضافة إلى ذلك، ينبغي تجنب الحمل لمدة&nbsp; شهر واحد بعد التطعيم.</p><p dir="RTL"><strong>المحاذير والإحتياطات:</strong></p><p dir="RTL">في حالات نادرة، من الممكن التقاط جدري الماء، بما في ذلك جدري الماء الشديد، من شخص أخذ لقاح تطعيمه فاريفاكس. وقد يحدث هذا في الأشخاص الذين لم يأخذوا اللقاح أو أصيبوا بجدري الماء، وكذلك الأشخاص الذين يندرجون ضمن إحدى الفئات التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأفراد الذين يعانون من ضعف الجهاز المناعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النساء الحوامل الذين لم يصابوا بجدري الماء أبدا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال الرُضع حديثي الولادة الذين لم تُصب أمهاتهم بجدري الماء أبدا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كلما كان ذلك ممكنا، يجب على الأفراد الذين أخذوا لقاح فاريفاكس تجنب الاتصال الوثيق، لمدة تصل إلى 6 أسابيع بعد أخذ اللقاح، مع أي شخص يقع في واحدة من الفئات المذكورة أعلاه. أخبر طبيبك إذا كان هناك أي شخص يقع في إحدى الفئات المذكورة أعلاه ومن المتوقع أن يكون على اتصال وثيق مع الشخص الذي أخذ اللقاح.</p><p dir="RTL"><br />تحدث إلى طبيبك أو الصيدلي قبل أن تتلقى أنت أو طفلك فاريفاكس:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أو لدى طفلك ضعف في جهاز المناعة (مثل عدوى فيروس نقص المناعة البشرية). يجب مراقبة وضعك أو وضع طفلك عن كثب لأن الاستجابة&nbsp; للقاح قد لا تكون كافية لضمان الحماية من المرض (انظر القسم 2 &quot;لا تستخدم فاريفاكس إذا&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى (أو لقاحات أخرى) و فاريفاكس:</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت أنت أو طفلك تتناول أو تناولت مؤخرا أي أدوية أخرى (أو أُعطيت لقاحات أخرى).</p><p dir="RTL">إذا كان من المقرر أن تتلقى أي نوع آخر من اللقاح في نفس الوقت مع فاريفاكس، سوف ينصحك طبيبك أو الممرض إذا كان ذلك ممكناً. يمكن إعطاء فاريفاكس في نفس وقت مع اللقاحات التالية خلال برنامج التطعيم الروتيني في مرحلة الطفولة: الحصبة، النّكاف، والحصبة الألمانيّة (الثلاثي الفيروسي)، واللقاحات ضد المستدمية النزلية من النوع ب (هيموفيلاس انفلونزا ب)، والتهاب الكبد الوبائي ب، والدفتيريا، والكزاز، والشاهوق (السعال الديكي)، ولقاح شلل الأطفال الذي يعطى عن طريق الفم.</p><p dir="RTL">يجب تأجيل التطعيم لمدة 5 أشهر على الأقل بعد تلقي أي نقل للدم أو للبلازما، أو الجلوبولين المناعي البشري العادي (وهو محلول مُعقّم من الأجسام المضادة المنتجة طبيعيًّا محضّرة من الدم البشري المتبرع به) أو الجلوبولين المناعي للحماق النطاقي (VZIG).</p><p dir="RTL">ينبغي ألا تتلقى أي جلوبولين مناعي، بما في ذلك VZIG، لمدة شهر واحد بعد تلقيك لقاح فاريفاكس ما لم يقرر الطبيب ضرورة ذلك.</p><p dir="RTL">يجب على من يتلقى لقاح فاريفاكس، أن يتجنب تناول المنتجات الدوائية التي تحتوي على الأسبرين (الساليسيلات) لمدة 6 أسابيع بعد التطعيم، لأن هذا قد يسبب حالة خطيرة تسمى متلازمة راي التي يمكن أن تؤثر على جميع أعضاء الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">يجب عدم إعطاء فاريفاكس للنساء الحوامل.</p><p dir="RTL">إذا كنت حاملًا أو مرضعة، تعتقدين أنك قد تكونين حاملا أو تخططين للحمل، استشيري طبيبك أو الصيدلي قبل أـن تتلقي التطعيم. أيضا، من المهم أن تتجنبي الحمل في غضون شهر واحد بعد تلقيك اللقاح. ولذلك يجب عليك استخدام وسيلة فعالة لمنع الحمل خلال هذا الوقت .</p><p dir="RTL">أخبري طبيبك إذا كنت تمارسين الرضاعة الطبيعية أو تنوين القيام بذلك. سوف يقرر طبيبك ما إذا كان يجب أن تتلقى فاريفاكس أثناء ذلك.</p><p dir="RTL"><br /><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا توجد معلومات تشير إلى أن فاريفاكس سوف يُؤثر على قدرتك على قيادة المركبات أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فاريفاكس على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول صوديوم (23 ملغ) لكل جرعة ، أي أنه &quot;خالي من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي فاريفاكس على البوتاسيوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول بوتاسيوم (39 ملغ) لكل جرعة ، أي أساسا &quot;خالية من البوتاسيوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم الطبيب أو مُقدم الرعاية الصحية بإعطائك لقاح فاريفاكس.</p><p dir="RTL">يُعطى فاريفاكس عن طريق الحقن على النحو التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرضّع بدءًا من 9 أشهر إلى 12 شهرا من العمر:</p><p dir="RTL">يمكن إعطاء فاريفاكس للرضّع بين 9 و 12 شهرا من العمر في ظروف خاصة (للتوافق مع جداول التطعيم الوطنية أو في حال تفشي الحماق). ولضمان الحماية المثلى ضد جدري الماء ، ينبغي إعطاء جرعتين من فاريفاكس تفصل بينهما مدة زمنية لا تقل عن ثلاثة أشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال بدءًا من 12 شهرا إلى 12 سنة من العمر:</p><p dir="RTL">لضمان الحماية المثلى ضد جدري الماء ، ينبغي إعطاء جرعتين من فاريفاكس تفصل بينهما مدة شهر واحد على الأقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأطفال من عمر 12 شهرا إلى 12 سنة المصابون بفيروس نقص المناعة البشرية بدون أعراض:</p><p dir="RTL">ينبغي إعطاء فاريفاكس كجرعتين عن طريق الحقن تفصل بينهما مدة 12 أسبوعا. یرجی طلب المزيد من المعلومات من مقدم الرعایة الصحیة الخاص بك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المراهقون بدءًا من عمر 13 سنة وما فوق والبالغون:</p><p dir="RTL">يعطى فاريفاكس كجرعتين عن طريق الحقن. وينبغي إعطاء الجرعة الثانية بعد مرور 4 إلى 8 أسابيع من الجرعة الأولى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تحديد عدد وتوقيت الجرعات من قبل الطبيب، وذلك باستخدام التوصيات الرسمية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي إعطاء فاريفاكس للأطفال دون سن 9 أشهر من العمر.<br />&nbsp;</p><p dir="RTL">يجب حقن فاريفاكس في العضل أو تحت الجلد إما في المنطقة الخارجية من الفخذ أو في الجزء العلوي من الذراع. ويفضل عادة عند الحقن في العضل، منطقة الفخذ عند الأطفال الصغار، في حين يُعد موضع الحقن المفضل لدى كبار السن، هو المنطقة العليا من الذراع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك اضطراب في تخثر الدم أو مستويات منخفضة من الصفائح الدموية في الدم، سوف تعطى الحقنة تحت الجلد.</p><p dir="RTL">سوف يحرص طبيبك أو مقدم الرعاية الصحية لديك على ألا يتم حقن فاريفاكس في مجرى الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تستخدم من فاريفاكس أكثر مما يجب</strong></p><p dir="RTL">من المستبعد جدًا أن تتلقى جرعة زائدة من فاريفاكس لأن اللقاح يتوفر في قوارير تحتوي كل منها على جرعة واحدة فقط ويعطى من قبل الطبيب أو الرعاية الصحية المهنية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت تعتقد أنك قد فاتتك جرعة من فاريفاكس</strong></p><p dir="RTL">اتصل بطبيبك الذي سيقرر ما إذا كنت بحاجة إلى جرعة والوقت المناسب لك لتتلقاها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية واللقاحات، يمكن أن يسبب هذا اللقاح أعراض جانبية لكنها لا تحدث لدى جميع من يتلقاه.</p><p dir="RTL">نادرا جدا (بُلغ عنها لدى أقل من شخص واحد من بين 10000 شخص)، قد يحدث رد فعل تحسسي شديد مع الأعراض التي قد تشمل تورم في الوجه، وانخفاض ضغط الدم، وصعوبة في التنفس، مع أو بدون طفح جلدي. غالبا ما تحدث هذه التفاعلات بعد الحقن بوقت قريب جدا. إذا لاحظت أي من هذه الأعراض أو أي أعراض خطيرة أخرى بعد التطعيم، يجب أن تطلب الرعاية الطبية الفورية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك إذا لاحظت أي من الأعراض الجانبية النادرة أو النادرة جدا التالية:</p><p dir="RTL">&bull; كدمات أو نزيف أكثر سهولة من المعتاد. بقع تحت الجلد حمراء أو أرجوانية بحجم رأس الدبوس، شحوب شديد</p><p dir="RTL">&bull; الطفح الجلدي الحاد (القرحات والبثور التي قد تشمل العينين والفم و / أو الأعضاء التناسلية؛ وبقع حمراء، مثيرة للحكة في كثير من الأحيان تبدأ على الأطراف وأحيانا على الوجه وبقية الجسم) (متلازمة ستيفنز جونسون، حمامى عديد الأشكال)</p><p dir="RTL">&bull; ضعف العضلات، والأحاسيس الغير طبيعيّة، ووخز في الذراعين والساقين والجزء العلوي من الجسم (متلازمة غيلان باريه)</p><p dir="RTL">&bull; الحمى، والشعور بالمرض، والتقيؤ، والصداع، وتيبس الرقبة والحساسية للضوء (التهاب السحايا)</p><p dir="RTL">&bull; السكتة الدماغية</p><p dir="RTL">&bull; النوبات (نوبات الصرع) مع أو بدون حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد لوحظت الأعراض الجانبية التالية:</p><p dir="RTL">ردود الفعل الشائعة جدا (أُبلغ عنها لدى أكثر من شخص واحد من بين 10 أشخاص):</p><p dir="RTL">&bull; حُمّى.</p><p dir="RTL">&bull; احمرار الجلد حول موضع الحقن، وألم / حساسية نحو اللمس / وجع، وتورم</p><p dir="RTL">&nbsp;</p><p dir="RTL">ردود الفعل الشائعة (أُبلغ عنها لدى أقل 1 من بين 10 ولكن أكثر من 1 من بين 100 شخص) هي:</p><p dir="RTL">&bull; عدوى الجهاز التنفسي العلوي (الأنف، الحلق، مجرى الهواء)</p><p dir="RTL">&bull; &nbsp;التيهج/ الإثارة</p><p dir="RTL">&bull; الطفح الجلدي، &nbsp;طفح جلدي مع جلد أحمر مسطح ونتوءات صغيرة متقاربة ، طفح جلدي يشبه الحماق</p><p dir="RTL">&bull; الطفح الجلدي والحكة في موضع الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL">ردود الفعل غير الشائعة (أُبلغ عنها لدى أقل من 1 من بين 100 &nbsp;شخص ولكن أكثر من 1 من بين 1000 شخص) هي:</p><p dir="RTL">&bull; صداع، نعاس</p><p dir="RTL">&bull; إفرازات وحكة في العينين مع تقشر الجفون (التهاب الملتحمة)</p><p dir="RTL">&bull; السعال، احتقان الأنف، احتقان الصدر، سيلان الأنف، وفقدان الشهية</p><p dir="RTL">&bull; اضطراب في المعدة مع القيء، وتشنجات، والإسهال الناجم عن فيروس</p><p dir="RTL">&bull; الإسهال، والتقيؤ (نزلة معويّة)</p><p dir="RTL">&bull; عدوى الأذن، والتهاب الحلق</p><p dir="RTL">&bull; البكاء، وعدم القدرة على النوم، واضطرابات النوم</p><p dir="RTL">&bull; الطفح الجلدي الناجم عن فيروس الحماق (جدري الماء)، والمرض الناجم عن فيروس، والتهاب الجلد ، احمرار في الجلد ، الشرى</p><p dir="RTL">&bull; الضعف / التعب، والشعور العام بالتوعك، وتفاعلات تحسسية في موضع الحقن بما في ذلك الطفح الجلدي مثل الشرى، وخدر، ونزيف، كدمات، تصلب المنطقة من الجلد وارتفاعها، والشعور بالدفىء، ودفئ الموضع عند اللمس .</p><p dir="RTL">&nbsp;</p><p dir="RTL">وكانت ردود الفعل النادرة (التي أُبلغ عنها عند أقل من شخص واحد من بين 1000 شخص ولكن أكثر من شخص واحد من بين 10،000 شخص) هي:</p><p dir="RTL">&bull; تورم الغدد، كدمات أو نزيف بسهولة أكثر من المعتاد</p><p dir="RTL">&bull; ، والهيجان، والنوم أكثر من اللازم ، وصعوبة المشي، والنوبات مع الحمى، والارتعاش</p><p dir="RTL">&bull; تورم الجفن، تهيج العين</p><p dir="RTL">&bull; ألم الأذن</p><p dir="RTL">&bull; الشعور باحتقان في الأنف المصحوب أحيانًا مع ألم نبضي وضغط في الوجه أو ألم (التهاب الجيوب الأنفية)، والعطس، وسيلان الأنف (التهاب الغشاء المخاطي للأنف) ، والصفير في التنفس، وتورم القنوات التنفسية في الرئتين (التهاب الشعب الهوائية)، عدوى الرئة، التهاب الرئة الحاد مع الحمى، قشعريرة، السعال، احتقان وضيق في التنفس (الالتهاب الرئوي).</p><p dir="RTL">&bull; مرض يشبه الإنفلونزا،.</p><p dir="RTL">&bull; آلام في المعدة، واضطراب في المعدة والشعور بالمرض ، والدم في البراز، وقرحة الفم</p><p dir="RTL">&bull; احمرار، بثور، اضطرابات جلدية (بما في ذلك كدمات الشرى)</p><p dir="RTL">&bull; آلام العضلات / العظام، آلام العضلات ، تيبس</p><p dir="RTL">&bull; تفاعلات في موضع الحقن بما في ذلك التغيرات في لون الجلد</p><p dir="RTL">&nbsp;</p><p dir="RTL">وتتضمن الأعراض الجانبية التي تم الإبلاغ عنها خلال مرحلة تسويق اللقاح ما يلي:</p><p dir="RTL">&bull; الأمراض التي تؤثر على الجهاز العصبي (الدماغ و / أو الحبل الشوكي)، ترهل عضلات الوجه وتدلى الجفن على جانب واحد من الوجه (شلل بيل)، والمشي بشكل غير مستقر، والدوخة، اغماء، وخز أو خدر اليدين والقدمين، التهاب الدماغ (التهاب المخ) ، والتهاب أغطيه الدماغ والحبل الشوكي لا تسببها العدوى البكتيرية (التهاب السحائي)</p><p dir="RTL">&bull; الهربيس النُطاقي، والتهاب الحلق (البلعوم)، وبقع أرجوانية أو حمراء مائلة إلى البني مرئية من خلال الجلد</p><p dir="RTL">(فرفرية هينوخ شونلين)، والالتهابات البكتيرية الثانوية في الجلد والأنسجة الليّنة بما في ذلك الحصف المُعدي والتهاب النسيج الخلوي، والحماق (جدري الماء)،فقر الدم اللاتنسجي، والذي قد يشمل كدمات أو نزيف أكثر سهولة من المعتاد. بقع تحت الجلد حمراء أو أرجوانية، مسطّحة، حجمها كرأس الدبوس ؛ شحوب شديد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. وهذا يشمل أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الأعراض الجانبیة مباشرة عن طريق المركز الوطني للتيقظ&nbsp; والسلامة الدوائية ، الهيئة العامة للغذاء والدواء &ndash; المملكة العربية السعودية. من خلال الإبلاغ عن الأعراض الجانبیة، یمکنك المساعدة في توفیر المزید من المعلومات حول سلامة الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا اللقاح بعيدا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا اللقاح بعد تاريخ انتهاء الصلاحية المُدون على العلبة بعد EXP. تاريخ انتهاء الصلاحية مُدون على كل من العلبة الخارجي والمُلصق الداخلي.</p><p dir="RTL">يُحفظ في الثلاجة (2 - 8 درجة مئوية). لا يُجمد. احرص على إبقاء الفيال داخل العلبة الخارجية من أجل حماية اللقاح من الضوء.</p><p dir="RTL">ينبغي استخدام اللقاح فورا بعد إعادة تشكيل مسحوق اللقاح إلى محلول. ومع ذلك، فإن ثباتية (فعالية) اللقاح للاستخدام أُثبتت لمدة 30 دقيقة بين 20 درجة مئوية و 25 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي لقاحات عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من اللقاحات التي لم تعد تستخدمها. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا &nbsp;يحتوي فاريفاكس </strong></p><p dir="RTL"><strong>المادة الفعالة هي</strong>: فيروس الحماق الحيّ المُضعّف (سلالة أوكا / ميرك) (اُنتج في خلايا بشرية مضاعفة MRC-5).</p><p dir="RTL">تحتوي كل جرعة 0.5 ملل من اللقاح بعد تحويله إلى محلول: ما لا يقل عن 1350 ب إف يو (وحدة تكوين نمو فيروسي) من فيروس الحماق (سلالة أوكا / ميرك).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المكونات الأخرى هي:</strong></p><p dir="RTL"><strong><u>مسحوق:</u></strong></p><p dir="RTL">السكروز (17 مجم)</p><p dir="RTL">جيلاتين متحلل (8.3 مجم)</p><p dir="RTL">اليوريا (3.5 مجم)</p><p dir="RTL">كلوريد الصوديوم (2.1 مجم)</p><p dir="RTL">إل-غلوتامات أحادي الصوديوم (0.33 مجم)</p><p dir="RTL">فوسفات الصوديوم ثنائي القاعدة (0.30 مجم)</p><p dir="RTL">فوسفات البوتاسيوم أحادي القاعدة (53 ميكروغرام)</p><p dir="RTL">كلوريد البوتاسيوم (53 ميكروغرام)</p><p dir="RTL">المكونات الأخرى الموجودة بكميات ضئيلة: النيومايسين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>مذيب:</u></strong></p><p dir="RTL">ماء مُعقّم مُخصص للحقن</p><p dir="RTL"><strong><!--[if !supportLineBreakNewLine]--><br /><!--[endif]--></strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو فاريفاكس وما هي محتويات العبوة </strong></p><p dir="RTL">الشكل الصيدلاني: مسحوق و مذيب لتعليق محلول للحقن</p><p dir="RTL">يتكون اللقاح من مسحوق أبيض إلى أبيض مائل إلى البيج في الفيال و محلول صافي بلا لون&nbsp; في الفيال. المنتج متوفر في عبوات تتكون من 1 - 10 جرعات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق و و الشركة المصنعة: </strong></p><p dir="RTL"><strong>الشركة المالكة لحقوق التسويق:<br />شركة ميرك شارب و دوهم ذ م م<br />770 سومنيتون بايك<br />ص ب 4<br />ويست بوينت، بي إيه 19486 ، الولايات المُتحدة</strong></p><p dir="RTL"><br /><strong>الشركة المصنعة :<br />شركة ميرك شارب و دوهم ذ م م<br />770 سومنيتون بايك<br />ص ب 4<br />ويست بوينت، بي إيه 19486 ، الولايات المُتحدة</strong></p><p dir="RTL"><br /><strong>و / أو:<br />شركة ميرك شارب و دوهمذ م م<br />5325 طريق أولد أوكسفورد<br />دورهام، إن سي 27712 ، الولايات المتحدة</strong></p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            سبتمبر 2022


للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa

•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة.


(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلاني الذي صرفها لك
- إن الطبيب والصيدلاني هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحه العرب
و اتحاد الصيادلة العرب

تمت الموافقة على نشرة المعلومات هذه للمريض من قبل الهيئة العامة الغذاء والدواء السعودية
 



المعلومات التالية مخصصة للمتخصصين في الرعاية الصحية فقط:
تعليمات
قبل إعادة التشكيل، تحتوي القارورة على مسحوق أبيض إلى أبيض مائل للون الأصفر وتحتوي الحقنة المملوءة مسبقًا على مذيب سائل واضح عديم اللون. اللقاح المعاد تشكيله هو سائل أصفر واضح عديم اللون إلى شاحب.
تجنب استخدام المطهرات عند إعداد اللقاح.
يجب استخدام المذيب المرفق في تشكيل مسحوق اللقاح إلى محلول. 
من المهم استخدام حقنة وإبرة معقمة منفصلة لكل مريض لمنع انتقال العوامل المعدية من فرد إلى آخر.
يجب استخدام إبرة واحدة لإعادة تشكيل المحلول وإبرة منفصلة وجديدة للحقن.

ارشادات لإعداد اللقاحات
لتثبيت الإبرة، يجب وضعها على طرف الحقنة وتأمينها عن طريق تدويرها ربع الدورة (90 درجة).

قم بحقن كامل محتوى الحقنة مملوءة مسبقا في القارورة التي تحتوي على مسحوق. قم بتحريك المزيج بلطف.

ينبغي فحص اللقاح المحلول بالعين المجردة بحثاً عن أي جسيمات وتغيير في اللون قبل إعطائها. 
لا ينبغي استخدام اللقاح بعد تحضيره على شكل محلول إذا لوحظت فيه  أي جسيمات أو إذا كان المحلول غير صافي ولم يكن عديم اللون أو مائل إلى الأصفر الشاحب.
يوصى بإعطاء اللقاح فور إعادة تشكيله، وذلك لتقليل فقدان الفعالية إلى أدنى حد. تخلص من اللقاح إذا لم يتم استخدامه في غضون 30 دقيقة.
لا تجمد اللقاح المعاد تشكيله.

قم بسحب كامل محتوى القارورة في حقنة، وتغيير الإبرة، و قم بحقن اللقاح عن طريق تحت الجلد أو داخل العضل.
أي منتج طبي غير مستعمل أو نفايات يجب التخلص منها وفقا للمتطلبات المحلية.
انظر أيضاً القسم 3 كيفية استخدام  فاريفاكس
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                VARIVAX® Refrigerator Stable Formulation Powder
Powder and solvent for suspension for injection 
Varicella Virus Vaccine Live (Oka/Merck)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                After reconstitution, one dose (0.5 mL) contains:

Varicella virus*	Oka/Merck strain (live, attenuated)	1350 PFU**
*   Produced in human diploid cells (MRC-5)
** PFU = Plaque-forming units

This vaccine may contain a trace amount of neomycin (see sections 4.3 and 4.4). For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Powder and solvent for suspension for injection.

White to off-white powder and clear, colourless liquid solvent.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VARIVAX is indicated for vaccination against varicella in individuals from 12 months of age (see sections 4.2 and 5.1).</p><p>&nbsp;</p><p>VARIVAX can be administered to infants from 9 months of age under special circumstances, such as to conform with national vaccination schedules or in outbreak situations (see sections 4.2, 4.5, and 5.1).</p><p>&nbsp;</p><p>VARIVAX may also be administered to susceptible individuals who have been exposed to varicella. Vaccination within 3 days of exposure may prevent a clinically apparent infection or modify the course of the infection. In addition, there are limited data that indicate that vaccination up to 5 days after exposure may modify the course of the infection (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Posology</em></p><p>The use of VARIVAX should be based on official recommendations. <u>Individuals less than 9 months of age</u></p><p>VARIVAX should not be administered to individuals less than 9 months of age.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Individuals from 9 months of age</u></p><p>Individuals should receive two doses of VARIVAX to ensure optimal protection against varicella (see section 5.1).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Individuals from 9 to 12 months of age</p><p>In settings in which vaccination is initiated between 9 and 12 months of age, a second dose is needed and should be given after a minimum interval of 3 months (see section 5.1).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Individuals from 12 months to 12 years of age</p><p>For individuals from 12 months to 12 years of age, at least one month must elapse between the first and second dose (see section 5.1).</p><p>&nbsp;</p><p><em>Note:</em><em> applicable official recommendations may vary regarding the need for one or two doses and the interval between doses of varicella-containing vaccines.</em></p><p><em>&nbsp;</em></p><p>Individuals 12 months to 12 years of age with asymptomatic HIV infection [CDC Class 1] with an age- specific CD4+ T-lymphocyte percentage &sup3;25% should receive two doses given 12 weeks apart.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Individuals from 13 years of age and older</p><p>Individuals from 13 years of age and older should receive two doses given 4-8 weeks apart. If the interval between doses exceeds 8 weeks, the second dose should be given as soon as possible (see section 5.1).</p><p>&nbsp;</p><p>There are data available on protective efficacy for up to 9 years postvaccination (see section 5.1). However, the need for booster doses has not been determined yet.</p><p>&nbsp;</p><p>If VARIVAX is to be administered to seronegative subjects before a period of planned or possible future immunosuppression (such as those awaiting organ transplantation and those in remission from a malignant disease), the timing of the vaccinations should take into account the interval after the second dose before maximal protection might be expected (see sections 4.3, 4.4, and 5.1).</p><p>&nbsp;</p><p>There are no data on protective efficacy or immune responses to VARIVAX in seronegative persons over 65 years of age.</p><p>&nbsp;</p><p><em>Method of administration</em></p><p><em>&nbsp;</em></p><p>The vaccine is to be injected intramuscularly (IM) or subcutaneously (SC).</p><p>The preferred injection sites are the anterolateral area of the thigh in younger children and the deltoid area in older children, adolescents, and adults.</p><p>The vaccine should be administered subcutaneously in patients with thrombocytopenia or any coagulation disorder.</p><p>&nbsp;</p><p>DO NOT INJECT INTRAVASCULARLY.</p><p><strong>&nbsp;</strong></p><p>Precautions to be taken before manipulating or administering the product: See section 6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to any varicella vaccine, to any of the excipients listed in section 6.1, or neomycin (which may be present as a trace residue, see sections 2 and 4.4).
•	Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the hemic and lymphatic systems.
•	Individuals receiving immunosuppressive therapy (including high doses of corticosteroids) (see section 4.8).
•	Severe humoral or cellular (primary or acquired) immunodeficiency, e.g. severe combined immunodeficiency, agammaglobulinaemia and AIDS or symptomatic HIV infection or an age- specific CD4+ T-lymphocyte percentage in children below 12 months: CD4+ <25%; children between 12-35 months: CD4+ <20%; children between 36-59 months: CD4+ <15% (see sections 4.4 and 4.8).
•	Individuals with a family history of congenital or hereditary immunodeficiency, unless the immune competence of the potential vaccine recipient is demonstrated.
•	Active untreated tuberculosis.
•	Any illness with fever >38.5ºC; however, low-grade fever itself is not a contraindication to vaccination.
•	Pregnancy. Furthermore, pregnancy should be avoided for 1 month following vaccination (see section 4.6).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p>As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic reaction following the administration of the vaccine.</p><p>&nbsp;</p><p>As for other vaccines, there is the possibility of hypersensitivity reactions, not only to the active principle, but also to any of the excipients listed in section 6.1 or neomycin (which may be present as a trace residue, see sections 2 and 4.3).</p><p>&nbsp;</p><p>As with other vaccines, VARIVAX does not completely protect all individuals from naturally acquired varicella. Clinical trials have only assessed efficacy beginning 6 weeks after a single dose in healthy individuals up to 12 years of age or 6 weeks after the second dose in older subjects (see section 5.1).</p><p>&nbsp;</p><p>Vaccination may be considered in patients with selected immune deficiencies where the benefits outweigh the risks (e.g., asymptomatic HIV subjects, IgG subclass deficiencies, congenital neutropenia, chronic granulomatous disease, and complement deficiency diseases).</p><p>&nbsp;</p><p>Immunocompromised patients who have no contraindication for this vaccination (see section 4.3) may not respond as well as immunocompetent subjects; therefore, some of these patients may acquire varicella in case of contact, despite appropriate vaccine administration. These patients should be monitored carefully for signs of varicella.</p><p>Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination (see section 4.5).<u>Transmission</u></p><p>Transmission of varicella vaccine virus (Oka/Merck strain) resulting in varicella infection including disseminated disease may rarely occur between vaccine recipients (who develop or do not develop a varicella-like rash) and contacts susceptible to varicella including healthy as well as high-risk individuals (see section 4.8).</p><p>&nbsp;</p><p>Therefore, vaccine recipients should attempt to avoid, whenever possible, close association with susceptible high-risk individuals for up to 6 weeks following vaccination.</p><p>&nbsp;</p><p>In circumstances where contact with high-risk individuals is unavoidable, before vaccination, the potential risk of transmission of the vaccine virus should be weighed against the risk of acquiring and transmitting the wild-type varicella virus (see section 4.8).</p><p>&nbsp;</p><p>Susceptible high-risk individuals include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Immunocompromised individuals (see section 4.3);</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pregnant women without documented positive history of chickenpox or laboratory evidence of prior infection;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; New-borns of mothers without documented positive history of chickenpox or laboratory evidence of prior infection.</p><p>&nbsp;</p><p><u>Sodium</u></p><p>This medicinal product contains less than 1 mmol (23 mg) sodium per dose and is considered to be essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p><p><u>Potassium</u></p><p>This medicinal product contains less than 1 mmol (39 mg) potassium per dose and is considered to be essentially &lsquo;potassium-free&rsquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>VARIVAX must not be mixed with any other vaccine or other medicinal product in the same syringe. Other injectable vaccines or other medicinal products must be given as separate injections and at different body sites.</p><p>&nbsp;</p><p><em>Concomitant administration with other vaccines</em></p><p>VARIVAX has been administered to toddlers at the same time as, but at a different injection site from, a combined measles, mumps, and rubella vaccine, <em>Haemophilus influenzae </em>type b conjugate vaccine, hepatitis B vaccine, diphtheria/tetanus/whole-cell pertussis vaccine, and oral polio virus vaccine. There was no evidence of a clinically relevant difference in the immune responses to any of the antigens when co-administered with VARIVAX. If varicella vaccine (live) (Oka/Merck strain) is not given concomitantly with measles, mumps, and rubella virus vaccine live, a 1-month interval between the 2 live virus vaccines should be observed.</p><p>&nbsp;</p><p>Concurrent administration of VARIVAX and tetravalent, pentavalent or hexavalent (diphtheria, tetanus, and acellular pertussis [DTaP])-based vaccines has not been evaluated.</p><p>&nbsp;</p><p>Vaccination should be deferred for at least 5 months following blood or plasma transfusions, or administration of normal human immune globulin or varicella zoster immune globulin (VZIG).</p><p>&nbsp;</p><p>Administration of varicella zoster virus antibody-containing blood products, including VZIG or other immune globulin preparations, within 1 month following a dose of VARIVAX may reduce the immune response to the vaccine and hence reduce its protective efficacy. Therefore, administration of any of these products should be avoided within 1 month after a dose of VARIVAX unless considered to be essential.</p><p>&nbsp;</p><p>Vaccine recipients should avoid use of salicylates for 6 weeks after vaccination with VARIVAX as Reye syndrome has been reported following use of salicylates during wild-type varicella infection (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Fertility</em></p><p>Animal reproduction studies have not been conducted with VARIVAX. VARIVAX has not been evaluated for potential to impair fertility.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>Pregnant women should not be vaccinated with VARIVAX.</p><p>&nbsp;</p><p>Studies have not been conducted with VARIVAX in pregnant women.</p><p>However, foetal damage has not been documented when varicella vaccines have been given to pregnant women. It is not known whether VARIVAX can cause foetal harm when administered to a pregnant woman or can affect reproduction capacity.</p><p>&nbsp;</p><p>Pregnancy should be avoided for 1 month following vaccination. Women who intend to become pregnant should be advised to delay.</p><p><em>Breast-feeding</em></p><p>Due to the theoretical risk of transmission of the vaccine viral strain from mother to infant, VARIVAX is not generally recommended for breast<em>-</em>feeding mothers (see also section 4.4). Vaccination of exposed women with negative history of varicella or known to be seronegative to varicella should be assessed on an individual basis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Summary of the safety profile</strong></p><p><strong>&nbsp;</strong></p><p>In clinical trials, frozen and refrigerator-stable formulations of varicella vaccine (live) (Oka/Merck strain) were administered to approximately 17,000 healthy individuals z12 months of age who were monitored for up to 42 days after each dose. There appeared to be no increased risk for adverse events with the use of VARIVAX in seropositive individuals. The safety profile of refrigerator-stable varicella vaccine (live) (Oka/Merck strain) was generally similar to the safety profile for earlier formulations of the vaccine.</p><p>&nbsp;</p><p>In a double-blind, placebo-controlled study among 956 healthy individuals 12 months to 14 years of age, 914 of whom were serologically confirmed to be susceptible to varicella, the only adverse events that occurred at a significantly greater rate in vaccine recipients than in placebo recipients were pain (26.7% versus 18.1%) and redness (5.7% versus 2.4%) at the injection site and non-injection-site varicella-like rash (2.2% versus 0.2%).</p><p>&nbsp;</p><p>In a clinical trial, 752 children received VARIVAX, either intramuscularly or subcutaneously. The general safety profile of either administration routes were comparable, although injection-site reactions were less frequent in the IM group (20.9%) compared with the SC group (34.3%).</p><p>&nbsp;</p><p>In a post-marketing study with varicella vaccine (live) (Oka/Merck strain), conducted to evaluate short- term safety (follow-up of 30 or 60 days) in approximately 86,000 children, 12 months to 12 years of age, and in 3600 individuals, 13 years of age and older, no vaccine-related serious adverse events were reported.</p><p>&nbsp;</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated summary of adverse reactions</p><p><strong>&nbsp;</strong></p><p><u>Clinical studies</u></p><p>&nbsp;</p><p>Across clinical studies in which causality was assessed (5185 subjects), the following adverse events were reported in temporal association with vaccination:</p><p>Adverse events are ranked under headings of frequency using the following convention:</p><p><em>Very common (</em><em>&sup3;1/10), Common (</em><em>&sup3;1/100, &lt;1/10), Uncommon (</em><em>&sup3;1/1000, &lt;1/100), Rare (</em><em>&sup3;1/10,000,</em></p><p><em>&lt;1/1000)</em></p><p><em><u>&nbsp;</u></em></p><p><em><u>Healthy individuals 12 months to 12 years of age (1 dose)</u></em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:480px"><tbody><tr><td><p><strong>Adverse events</strong></p></td><td><p><strong>Frequency</strong></p></td></tr><tr><td colspan="2"><p><em>Blood and the lymphatic system disorders</em></p></td></tr><tr><td><p>Lymphadenopathy, Lymphadenitis, Thrombocytopenia</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Nervous system disorders</em></p></td></tr><tr><td><p>Headache, Somnolence</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Apathy, Agitation, Hypersomnia, Gait abnormality, Febrile seizure, Tremor</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Eye disorders</em></p></td></tr><tr><td><p>Conjunctivitis</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Acute conjunctivitis, Tearing, Oedema of the eyelid, Irritation</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td><p>Ear pain</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td><p>Cough, Nasal congestion, Respiratory congestion, Rhinorrhoea</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Sinusitis, Sneezing, Pulmonary congestion, Rhinitis, Wheezing, Bronchitis, Respiratory infection, Pneumonia</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td><p>Anorexia</p></td><td><p>Uncommon</p></td></tr><tr><td colspan="2"><p><em>Infections and infestations</em></p></td></tr><tr><td><p>Upper respiratory infection</p></td><td><p>Common</p></td></tr><tr><td><p>Gastroenteritis, Otitis, Otitis media, Pharyngitis, Varicella, Viral exanthema, Viral infection</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Infection, Flu-like illness</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td><p>Diarrhoea, Vomiting</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Abdominal pain, Nausea, Haematochezia, Mouth ulcer</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td><p>Rash, Maculopapular rash, Varicella-like rash (generalised median 5 lesions)</p></td><td><p>Common</p></td></tr><tr><td><p>Contact dermatitis, Erythema, Pruritus, Urticaria</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Flushing, Vesicle, Atopic dermatitis, Hive-like rash, Contusion, Dermatitis, Drug eruption, Skin infection</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Musculoskeletal and connective site conditions</em></p></td></tr><tr><td><p>Musculoskeletal pain, Myalgia, Stiffness</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Vascular disorders</em></p></td></tr><tr><td><p>Extravasation</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td><p>Fever</p></td><td><p>Very common</p></td></tr><tr><td><p>Injection site erythema, Rash, Pain/Tenderness/Soreness, Swelling, and Varicella-like rash (injection site median 2 lesions)</p></td><td><p>Common</p></td></tr><tr><td><p>Asthenia/Fatigue, Injection site ecchymosis, Haematoma, Induration, Rash, Malaise</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Injection site eczema, Lump, Warmth, Hive-like rash, Discolouration, Inflammation, Stiffness, Oedema/Swelling, Warm sensation, Warm to touch</p></td><td><p>Rare</p></td></tr><tr><td colspan="2"><p><em>Psychiatric disorders</em></p></td></tr><tr><td><p>Irritability</p></td><td><p>Common</p></td></tr><tr><td><p>Crying, Insomnia, Sleep disorder</p></td><td><p>Uncommon</p></td></tr></tbody></table><p>&nbsp;</p><p><em>&nbsp;</em></p><p><em><u>Healthy individuals 12 months to 12 years of age (2 doses received &ge; 3 months apart)</u></em></p><p><em>&nbsp;</em></p><p>The following serious adverse events temporally associated with the vaccination were reported in individuals 12 months to 12 years of age given varicella vaccine (live) (Oka/Merck strain): diarrhoea, febrile seizure, fever, post-infectious arthritis, vomiting.</p><p>&nbsp;</p><p>The rates of systemic clinical adverse events after a second dose of VARIVAX were generally similar to, or lower than, those seen with the first dose. The rates of injection-site reactions (primarily erythema and swelling) were higher after a second dose (see section 5.1 for study description).</p><p>&nbsp;</p><p><em><u>Healthy individuals 13 years of age and older (majority received 2 doses 4 to 8 weeks apart)</u></em></p><p><em>&nbsp;</em></p><p>Causality was not assessed in individuals 13 years of age and older with the exception of serious adverse events.</p><p>However, across clinical studies (1648 subjects) the following events were temporally associated with vaccination:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:437px"><tbody><tr><td><p><strong>Adverse events</strong></p></td><td><p><strong>Frequency</strong></p></td></tr><tr><td colspan="2"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td><p>Varicella-like rash (generalised median 5 lesions)</p></td><td><p>Common</p></td></tr><tr><td colspan="2"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td><p>Fever &sup3;37.7&deg;C oral,<em> </em>Injection‑site<em> </em>erythema, Soreness and Swelling</p></td><td><p>Very common</p></td></tr><tr><td><p>Injection‑site rash, Pruritus and<em> </em>Varicella-like rash (injection site median 2 lesions)</p></td><td><p>Common</p></td></tr><tr><td><p>Injection‑site ecchymosis, Haematoma, Induration, Numbness and Warmth</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Hyperpigmentation, Stiffness</p></td><td><p>Rare</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Post-Marketing Surveillance</u></p><p>&nbsp;</p><p>The following adverse events have been spontaneously reported in temporal relation to VARIVAX during worldwide post-marketing use:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:630px"><tbody><tr><td><p><strong>Adverse events<sup>+</sup></strong></p></td></tr><tr><td><p><em>Blood and the lymphatic system disorders</em></p></td></tr><tr><td><p>Aplastic anaemia, Thrombocytopenia (including idiopathic thrombocytopenic purpura (ITP)), Lymphadenopathy</p></td></tr><tr><td><p><em>Nervous system disorders</em></p></td></tr><tr><td><p>Cerebrovascular accident, Febrile and non-febrile convulsions, Guillain-Barr&eacute; syndrome, Transverse myelitis, Bell&rsquo;s palsy, Ataxia*, Vertigo/Dizziness, Paraesthesia, Syncope</p></td></tr><tr><td><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td><p>Pneumonitis</p></td></tr><tr><td><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td><p>Stevens-Johnson syndrome, Erythema multiforme, Henoch-Sch&ouml;nlein purpura, Secondary bacterial infections of skin and soft tissues, including Cellulitis</p></td></tr><tr><td><p><em>Infections and infestations</em></p></td></tr><tr><td><p>Encephalitis*<sup>&Dagger;</sup>, Pharyngitis, Pneumonia*, Varicella (vaccine strain), Herpes zoster*<sup>&Dagger;</sup>, Aseptic meningitis<sup>&Dagger;</sup></p></td></tr><tr><td><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td><p>Irritability</p></td></tr><tr><td><p><em>Immune system disorders</em></p></td></tr><tr><td><p>Anaphylaxis (including anaphylactic shock) and related phenomena such as Angioneurotic Oedema, Facial Oedema, and Peripheral Oedema, Anaphylaxis in individuals with or without an allergic history</p></td></tr><tr><td><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td><p>Nausea, Vomiting</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><sup>+</sup> </strong>Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. Consequently, the frequency of these adverse events is qualified as &quot;not known&quot;.</p><p>* These selected adverse events reported with varicella vaccine (live) (Oka/Merck strain) are also a consequence of wild-type varicella infection. There is no indication of an increased risk of these adverse events following vaccination compared with wild-type disease from active post-marketing surveillance studies or passive post-marketing surveillance reporting (see section 5.1).</p><p><sup>&Dagger;</sup> See section c.</p><p>&nbsp;</p><p>Postvaccination rashes in which the Oka/Merck strain was isolated were generally mild (see section 5.1).</p><p>&nbsp;</p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Description of selected adverse reactions</p><p><strong>&nbsp;</strong></p><p><u>Cases of herpes zoster in clinical studies</u></p><p>In clinical trials, 12 cases of herpes zoster have been reported in 9543 vaccinated individuals 12 months to 12 years of age during 84,414 person-years of follow-up. This resulted in a calculated incidence of at least 14 cases per 100,000 person-years, compared with 77 cases per 100,000 person-years following wild-type varicella infection. In 1652 vaccinated individuals 13 years of age and older, 2 cases of herpes zoster were reported. All 14 cases were mild and no sequelae were reported.</p><p>&nbsp;</p><p>In another clinical study in individuals 12 months to 12 years of age, there were 2 cases of herpes zoster reported in the group receiving one dose of the vaccine and no cases were reported in the two-dose group. The subjects were followed for 10 years postvaccination.</p><p>&nbsp;</p><p>Active surveillance data in children vaccinated with varicella vaccine (live) (Oka/Merck strain) and followed for 14 years after vaccination showed no increase in the frequency of herpes zoster compared to children with prior wild-type varicella during the pre-vaccine era. However, the long-term effect of varicella vaccine (live) (Oka/Merck strain) on the incidence of herpes zoster is unknown at present (see section 5.1).</p><p><u>Complications associated with varicella</u></p><p>Complications of varicella from vaccine strain, including herpes zoster and disseminated disease such as aseptic meningitis and encephalitis, have been reported in immunocompromised or immunocompetent individuals.</p><p>&nbsp;</p><p><u>Transmission</u></p><p>Based on isolated case reports from post-marketing surveillance, the vaccine virus may rarely be transmitted to contacts of vaccinees who develop or do not develop a varicella-like rash (see section 4.4).</p><p>&nbsp;</p><p><u>Concomitant use of varicella vaccine (live) (Oka/Merck strain) with other paediatric vaccines</u></p><p>When varicella vaccine (live) (Oka/Merck strain) was given concurrently with measles, mumps, rubella vaccine (M-M-R II) to 12- to 23-month-old individuals, fever (&sup3;38.9&deg;C; oral equivalent, Days 0 to 42 postvaccination) was reported at a rate of 26-40% (see also section 4.5).</p><p>&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other special population</p><p><strong>&nbsp;</strong></p><p><u>Immunocompromised individuals (see section 4.3)</u></p><p>Necrotising retinitis has been reported post-marketing in immunocompromised individuals.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Clinical trial experience has not identified differences in the safety profile between the elderly (individuals</p><p>&sup3;65 years of age) and younger subjects.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after Authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report</strong><strong> any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><u>&nbsp;</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Accidental administration of more than the recommended dose of varicella vaccine (live) (Oka/Merck strain) has been reported (either a larger dose than recommended was injected, more than one injection was given, or the interval between injections was shorter than that recommended). Of these cases, the following adverse events were reported: injection-site redness, soreness, inflammation; irritability; gastrointestinal complaints (i.e., haematemesis, faecal emesis, gastroenteritis with vomiting and diarrhoea); cough and viral infection. None of the cases had long-term sequelae.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: virus vaccines - varicella live attenuated</p><p>ATC code: J07BK01</p><p><em>&nbsp;</em></p><p><em>Evaluation of clinical efficacy</em></p><p><em>&nbsp;</em></p><p><em>Efficacy in individuals less than 12 months of age</em></p><p>Clinical efficacy has not been evaluated when vaccination was initiated at less than 12 months of age.</p><p><em>&nbsp;</em></p><p><em>One-dose regimen in healthy individuals 12 months to 12 years of</em><em> age</em></p><p>In combined clinical trials using earlier formulations of the varicella vaccine (live) (Oka/Merck strain) at doses ranging from approximately 1000 to 17,000 PFU, the majority of subjects who received the varicella vaccine (live) (Oka/Merck strain) and were exposed to wild-type virus were either completely protected from chickenpox or developed a milder form of the disease.</p><p>&nbsp;</p><p>In particular, the protective efficacy of varicella vaccine (live) (Oka/Merck strain) beginning 42 days postvaccination was evaluated in three different ways:</p><p>&nbsp;</p><p>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by a double-blind, placebo-controlled trial over 2 years (N=956; efficacy 95 to 100%; formulation containing 17,430 PFU);</p><p>&nbsp;</p><p>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by assessment of protection from disease following household exposure over 7 to 9 years of observation (N=259; efficacy 81 to 88%; formulation containing 1000-9000 PFU); and</p><p>&nbsp;</p><p>3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; by comparing chickenpox rates over 7 to 9 years in vaccinees versus historical control data from 1972 through 1978 (N=5404; efficacy 83 to 94%; formulation containing 1000-9000 PFU).</p><p>&nbsp;</p><p>In a group of 9202 individuals 12 months to 12 years of age who had received a dose of the varicella vaccine (live) (Oka/Merck strain), 1149 cases of infection (occurring more than 6 weeks postvaccination) were observed over a follow-up period of up to 13 years. Out of these 1149 cases, 20 (1.7%) were classified as severe (number of lesions &sup3;300, oral body temperature &sup3;37.8&deg;C). The above-mentioned data, compared with the 36% proportion of severe cases observed following the wild-type virus infection in the unvaccinated historical controls, corresponds to a 95% relative decrease in the proportion of severe cases observed in the vaccinees who acquired infection after vaccination.</p><p>&nbsp;</p><p>Prophylaxis of varicella by vaccination up to 3 days following exposure has been investigated in two small controlled trials. The first study demonstrated that none of 17 children developed varicella following household exposure compared with 19 of 19 unvaccinated contacts. In a second placebo-controlled trial of post-exposure prophylaxis, one of 10 children in the vaccine group versus 12 of 13 in the placebo group developed varicella. In an uncontrolled trial in a hospital setting, 148 patients, of whom 35 were immunocompromised, received a dose of varicella vaccine 1 to 3 days post-exposure and none developed varicella.</p><p>&nbsp;</p><p>Published data on prevention of varicella at 4 to 5 days post-exposure are limited. In a double-blind trial, 26 susceptible siblings of children with active varicella were randomized to placebo or varicella vaccine. In the varicella vaccine group, 4 of 13 children (30.8%) developed varicella, of whom 3 children were vaccinated on Days 4 to 5. However, the disease was mild (1, 2, and 50 lesions). In contrast, 12 of 13 children (92.3%) in the placebo group developed typical varicella (60 to 600 lesions). Thus, vaccination 4 to 5 days after exposure to varicella may modify the course of any secondary cases of varicella.</p><p>&nbsp;</p><p><em>Two-dose regimen in healthy individuals 12 months to 12 years of age</em></p><p>In a study comparing 1-dose (N=1114) and 2-doses (N=1102) given 3 months apart, the estimated efficacy against all severities of varicella disease for the 10-year observation period was 94% for 1-dose and 98% for 2 doses (p&lt;0.001). The cumulative rate of varicella over the 10-year observation period was 7.5% after 1 dose and 2.2% after 2 doses. Most cases of varicella reported in recipients of 1 dose or 2 doses were mild.</p><p>&nbsp;</p><p><em>Two-dose regimen in healthy individuals 13 years of age and older</em></p><p>Protective efficacy following two doses given 4 or 8 weeks apart in individuals 13 years of age or older was evaluated based on household exposure over 6 to 7 years after vaccination. The clinical efficacy rate ranged from approximately 80 to 100%.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity of varicella vaccine (live) (Oka/Merck strain)</u></p><p><em>One-dose regimen in individuals 12 months to 12 years of</em><em> age</em></p><p>Clinical studies have established that the immunogenicity of the refrigerator-stable formulation is similar to the immunogenicity of earlier formulations that were evaluated for efficacy.</p><p>&nbsp;</p><p>A titre &sup3;5 gpELISA units/mL (gpELISA is a highly sensitive assay that is not commercially available) at 6 weeks postvaccination has been shown to be an approximate correlate of clinical protection. However, it is not known whether a titre of &sup3;0.6 gpELISA units/mL correlates with long-term protection.</p><p>&nbsp;</p><p><u>Humoral immune response in individuals 12 months to 12 years of age</u></p><p>Seroconversion (based on assay cut-off that generally corresponds to &sup3;0.6 gpELISA units/mL) was observed in 98% of 9610 susceptible individuals 12 months to 12 years of age who received doses ranging from 1000 to 50,000 PFU. Varicella antibody titres &sup3;5 gpELISA units/mL were induced in approximately 83% of these individuals.</p><p>&nbsp;</p><p>In individuals 12 to 23 months of age, the administration of VARIVAX refrigerated (8000 PFU/dose or 25,000 PFU/dose) induced varicella antibody titres &sup3;5 gpELISA units/mL at 6 weeks postvaccination, in 93% of individuals vaccinated.</p><p>&nbsp;</p><p><u>Humoral immune response in individuals 13 years of age and older</u></p><p>In 934 individuals 13 years of age and older, several clinical trials with varicella vaccine (live) (Oka/Merck strain) at doses ranging from approximately 900 to 17,000 PFU, have shown a</p><p>seroconversion rate (varicella antibody titre &sup3;0.6 gpELISA units/mL) after 1 dose of vaccine ranging from 73 to 100%. The proportion of subjects with antibody titres &sup3;5 gpELISA units/mL ranged from 22 to 80%.</p><p>&nbsp;</p><p>After 2 doses of vaccine (601 subjects) at doses ranging from approximately 900 to 9000 PFU, the seroconversion rate ranged from 97 to 100% and the proportion of subjects with antibody titres &sup3;5 gpELISA units/mL ranged from 76 to 98%.</p><p>&nbsp;</p><p>There are no data on immune responses to VARIVAX in Varicella-zoster virus (VZV)-seronegative persons &sup3;65 years of age.</p><p><u>Humoral immunity according to route of administration</u></p><p>A comparative study in 752 subjects who received VARIVAX either by intramuscular route or subcutaneous route demonstrated a similar immunogenicity profile with both administration routes.</p><p>&nbsp;</p><p><em>Two-dose regimen in healthy individuals 12 months to 12 years of age</em></p><p>In a multicentre study, healthy children 12 months to 12 years of age received either 1 dose of VARIVAX or 2 doses administered 3 months apart. The immunogenicity results are shown in the following table.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>VARIVAX</p><p>1-Dose Regimen (N = 1114)</p></td><td colspan="2" style="vertical-align:top"><p>VARIVAX</p><p>2-Dose Regimen (N = 1102)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>6 Weeks</p><p>Postvaccination</p></td><td style="vertical-align:top"><p>6 Weeks Post-dose 1</p></td><td style="vertical-align:top"><p>6 Weeks Post-dose 2</p></td></tr><tr><td style="vertical-align:top"><p>Seroconversion Rate</p></td><td style="vertical-align:top"><p>98.9% (882/892)</p></td><td style="vertical-align:top"><p>99.5% (847/851)</p></td><td style="vertical-align:top"><p>99.9% (768/769)</p></td></tr><tr><td style="vertical-align:top"><p>Percent with VZV Antibody Titre &ge;5 gpELISA units/mL</p><p>(Seroprotection Rate)</p></td><td style="vertical-align:top"><p>84.9% (757/892)</p></td><td style="vertical-align:top"><p>87.3% (743/851)</p></td><td style="vertical-align:top"><p>99.5% (765/769)</p></td></tr><tr><td style="vertical-align:top"><p>Geometric mean Titres</p><p>(gpELISA units/mL)</p></td><td style="vertical-align:top"><p>12.0</p></td><td style="vertical-align:top"><p>12.8</p></td><td style="vertical-align:top"><p>141.5</p></td></tr></tbody></table><p>&nbsp;</p><p>The results from this study and other studies in which a second dose of vaccine was administered 3 to 6 years after the initial dose demonstrate significant boosting of the VZV antibody response with a second dose. VZV antibody levels after 2 doses given 3 to 6 years apart are comparable to those obtained when the 2 doses are given 3 months apart. The seroconversion rates were approximately 100% after the first dose and 100% after the second dose. The vaccine seroprotection rates (&ge;5 gpELISA units/mL) were approximately 85% after the first and 100% after the second dose and the geometric mean titre (GMT) rose an average of approximately 10-fold after the second dose (for safety see section 4.8).</p><p>&nbsp;</p><p><em>Two-dose regimen in healthy individuals 9 to 12 months of age at the time of first dose</em></p><p><em>&nbsp;</em></p><p>A clinical study was conducted with the combined measles, mumps, rubella and varicella (Oka/Merck) (MMRV) vaccine administered with a 2-dose schedule, the doses being given 3 months apart in 1,620 healthy subjects from 9 to 12 months of age at the time of first dose.</p><p>&nbsp;</p><p>The safety profile post-dose 1 and 2 was generally comparable for all age cohorts.</p><p>&nbsp;</p><p>In the Full Analysis Set (vaccinated subjects regardless of their antibody titre at baseline), seroprotection rates of 100% were elicited to varicella post-dose 2, regardless of the age of the vaccinee at the first dose.</p><p>&nbsp;</p><p>The seroprotection rates and geometric mean titres (GMTs) to varicella for the Full Analysis Set are provided in the following table.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>MMRV Vaccine Dose 1 at 9 months /</p><p>Dose 2 at 12 months</p><p>(N = 527)</p></td><td colspan="2" style="vertical-align:top"><p>MMRV Vaccine Dose 1 at 11 months /</p><p>Dose 2 at 14 months</p><p>(N = 480)</p></td><td colspan="2" style="vertical-align:top"><p>MMRV Vaccine Dose 1 at 12 months /</p><p>Dose 2 at 15 months</p><p>(N = 466)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>6 Weeks</p><p>Post-dose 1</p></td><td style="vertical-align:top"><p>6 Weeks</p><p>Post-dose 2</p></td><td style="vertical-align:top"><p>6 Weeks</p><p>Post-dose 1</p></td><td style="vertical-align:top"><p>6 Weeks Post-dose</p><p>2</p></td><td style="vertical-align:top"><p>6 Weeks</p><p>Post-dose 1</p></td><td style="vertical-align:top"><p>6 Weeks Post-dose</p><p>2</p></td></tr><tr><td style="vertical-align:top"><p>Seroprotection rate to varicella [95% CI]</p><p>(titre &ge;5 gpELISA units/mL)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>93.1%</p><p>[90.6; 95.1]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100%</p><p>[99.3; 100]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>97.0%</p><p>[95.1; 98.4]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100%</p><p>[99.2;</p><p>100]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>96.5%</p><p>[94.4; 98.0]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>100%</p><p>[99.2; 100]</p></td></tr><tr><td style="vertical-align:top"><p>Geometric mean titres</p><p>[95% CI]</p><p>(gpELISA units/mL)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>12</p><p>[12; 13]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>321</p><p>[293; 352]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15</p><p>[14; 15]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>411</p><p>[376; 450]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>15</p><p>[14; 15]</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>481</p><p>[441; 526]</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Duration of immune response</em></p><p><em>One-dose regimen in individuals 12 months to 12 years of age</em></p><p>In those clinical studies involving healthy individuals 12 months to 12 years of age who have been followed long-term after single-dose vaccination, detectable varicella antibodies (gpELISA z0.6 units/ mL) were present in 99.1% (3092/3120) at 1 year, 99.4% (1382/1391) at 2 years, 98.7% (1032/1046) at 3</p><p>years, 99.3% (997/1004) at 4 years, 99.2% (727/733) at 5 years, and 100% (432/432) at 6 years postvaccination.</p><p>&nbsp;</p><p><em>Two-dose regimen in individuals 12 months to 12 years of age</em></p><p>Over 9 years of follow-up, the GMTs and percent of subjects with VZV antibody titres z5 gpELISA units/ mL in the 2-dose recipients were higher than those in the 1-dose recipients for the first year of follow-up and comparable during the entire follow-up period. The cumulative rate of VZV antibody persistence with both regimens remained very high at year 9 (99.0% for the 1-dose group and 98.8% for the 2-dose group).</p><p>&nbsp;</p><p><u>Individuals 13 years of age and older</u></p><p>In clinical studies involving healthy individuals 13 years of age and older who received 2 doses of vaccine, detectable varicella antibodies (gpELISA &sup3;0.6 units/mL) were present in 97.9% (568/580) at 1 year, 97.1% (34/35) at 2 years, 100% (144/144) at 3 years, 97.0% (98/101) at 4 years, 97.5% (78/80) at 5 years, and 100% (45/45) at 6 years postvaccination.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Freeform_x0020_7"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:379.2pt;margin-top:32.7pt;width:2.8pt;height:1pt;z-index:-251654144;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' coordsize="56,20" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" o:allowincell="f" path="m55,l,,,12r55,l55,xe" fillcolor="black" stroked="f">
 <v:path arrowok="t" o:connecttype="custom" o:connectlocs="34925,0;0,0;0,7620;34925,7620;34925,0"
  o:connectangles="0,0,0,0,0"/>
 <w:wrap anchorx="page"/>
</v:shape><![endif]--><img width="3" height="1" src="file:///C:/Users/aldails/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png" />A boost in antibody levels has been observed in vaccinees following exposure to wild-type varicella, which could account for the apparent long-term persistence of antibody levels after vaccination in these studies. The duration of immune response following administration of varicella vaccine (live) (Oka/Merck strain) in the absence of wild-type boosting is unknown (see section 4.2).</p><p>&nbsp;</p><p>Immune memory was demonstrated by administering a booster dose of varicella vaccine (live) (Oka/Merck strain) 4 to 6 years after the first vaccination in 419 individuals who were 1 to 17 years of age at the time of the first injection. The GMT prior to the booster dose was 25.7 gpELISA units/mL and increased to 143.6 gpELISA units/mL approximately 7-10 days after the booster dose.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><u>Effectiveness of varicella vaccine (live) (Oka/Merck strain)</u></strong></p><p><strong><u>&nbsp;</u></strong></p><p><u>Observational studies of long-term effectiveness of VARIVAX</u></p><p>Surveillance data from two U.S. observational effectiveness studies confirmed that widespread varicella vaccination reduces the risk of varicella by approximately 90%. Furthermore, the reduced risk of varicella was maintained at the population level over at least 15 years both in vaccinated and unvaccinated individuals. The data also suggest that varicella vaccination may reduce the risk of herpes zoster in vaccinated individuals.</p><p>&nbsp;</p><p>In the first study, a long-term prospective cohort study, approximately 7,600 children vaccinated in 1995 with varicella vaccine in their second year of life were actively followed for 14 years in order to estimate the occurrence of varicella and herpes zoster. By the end of the study in 2009, 38% of the study children were known to have received a second dose of varicella vaccine. Of note, in 2006, a second dose of varicella vaccine was recommended in the U.S. Over the entire follow-up, the incidence of varicella was approximately 10-fold lower among vaccinees than among children of the same age in the pre-vaccine era (estimated vaccine effectiveness over the study period was between 73% and 90%). Regarding herpes zoster, there were fewer herpes zoster cases among varicella vaccinees during the follow-up period than expected from rates in children of the same age with prior wild-type varicella during the pre-vaccine era (relative risk = 0.61, 95% CI 0.43 - 0.89). Breakthrough varicella and zoster cases were usually mild.</p><p>&nbsp;</p><p>In a second long-term surveillance study, five cross-sectional surveys on varicella incidence, each from a random sample of approximately 8,000 children and adolescents 5 to 19 years of age, were conducted over 15 years, from 1995 (pre-vaccine) through 2009. Results showed a gradual decline of varicella rates by an overall 90% to 95% (approximately 10- to 20-fold) from 1995 to 2009 in all age groups, both in vaccinated and unvaccinated children and adolescents. In addition, a decrease by approximately 90% (approximately 10-fold) in varicella hospitalisation rates was observed in all age groups.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evaluation of pharmacokinetic properties is not required for vaccines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traditional preclinical safety studies were not performed, but there are no preclinical concerns considered relevant to clinical safety beyond data included in other sections of the SPC.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><em>Powder:</em></p><p>Sucrose (17 mg)</p><p>Hydrolyzed Gelatin (8.3 mg)</p><p>Urea (3.5 mg)</p><p>Sodium chloride (2.1 mg)</p><p>Monosodium L-glutamate (0.33 mg)</p><p>Sodium Phosphate Dibasic (0.30 mg)</p><p>Potassium Phosphate Monobasic (53 &mu;g)</p><p>Potassium chloride (53 &mu;g)</p><p>&nbsp;</p><p>For information regarding residual components in trace quantities, see sections 2, 4.3 and 4.4.</p><p>&nbsp;</p><p><em>Solvent:</em></p><p>Water for Injections</p><p>Incompatibilities</p><p><strong>&nbsp;</strong></p><p>The vaccine must not be mixed with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
After reconstitution, the vaccine should be used immediately. However, the in-use stability has been demonstrated for 30 minutes between +20℃ and +25℃.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2<sup>o</sup>C - 8<sup>o</sup>C). Keep vial in the outer carton to protect from light.</p><p>&nbsp;</p><p><strong>Do not freeze.</strong></p><p>For storage conditions after the reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Powder in a vial (glass) with a stopper (butyl rubber) and flip off cap (aluminium) and solvent in a vial (glass) with a stopper (chlorobutyl rubber) and flip off cap (aluminium) in a pack size of 1 or 10.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p>Before reconstitution, the vial contains a white to off-white powder and the pre-filled syringe contains a clear, colourless liquid solvent. The reconstituted vaccine is a clear, colourless to pale yellow liquid.</p><p>&nbsp;</p><p>Avoid contact with disinfectants.</p><p>&nbsp;</p><p>To reconstitute the vaccine, use only the solvent provided in the pre-filled syringe.</p><p>&nbsp;</p><p>It is important to use a separate sterile syringe and needle for each patient to prevent transmission of infectious agents from one individual to another.</p><p>&nbsp;</p><p>One needle should be used for reconstitution and a separate, new needle for injection.</p><p><em>&nbsp;</em></p><p><em>Directions for the vaccine preparation</em></p><p><em>&nbsp;</em></p><p>To attach the needle, it should be firmly placed on the tip of the syringe and secured by rotating a quarter of a turn (90&deg;).</p><p>&nbsp;</p><p>Inject the entire content of the pre-filled syringe into the vial containing the powder. Gently agitate to mix thoroughly.</p><p>&nbsp;</p><p>The reconstituted vaccine should be inspected visually for any foreign particulate matter and/or variation in physical appearance. The vaccine must not be used if any particulate matter is noted or if the appearance is not a clear colourless to pale yellow liquid after reconstitution.</p><p>&nbsp;</p><p>&nbsp;</p><p>It is recommended that the vaccine be administered immediately after reconstitution, to minimize loss of potency. Discard if reconstituted vaccine is not used within 30 minutes.</p><p><strong>&nbsp;</strong></p><p><strong>Do not freeze the reconstituted vaccine.</strong></p><p><strong>&nbsp;</strong></p><p>Withdraw the entire content of the vial into a syringe, change the needle, and inject the vaccine by subcutaneous or intramuscular route.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Merck Sharp & Dohme LLC
770 Sumneytown Pike
P.O. Box 4
West Point, PA 19486, US

Manufacturers:
Merck Sharp & Dohme LLC
770 Sumneytown Pike
P.O. Box 4
West Point, PA 19486, US

And/Or:
Merck Sharp & Dohme LLC
5325 Old Oxford Road
Durham, NC 27712, US
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sep 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>